258 related articles for article (PubMed ID: 37256379)
1. A review of heart transplant immunosuppressants and nonmelanoma skin cancer.
Eckembrecher DG; Eckembrecher FJ; Camacho I; Shah H; Dave Y; Patel S; Nouri K
Arch Dermatol Res; 2023 Nov; 315(9):2491-2503. PubMed ID: 37256379
[TBL] [Abstract][Full Text] [Related]
2. Expression of Bcl-xL and Mcl-1 in the nonmelanoma skin cancers of renal transplant recipients.
Burke MT; Morais C; Oliver KA; Lambie DL; Gobe GC; Carroll RP; Staatz CE; Sinnya S; Soyer HP; Winterford C; Haass NK; Campbell SB; Isbel NM
Am J Clin Pathol; 2015 Apr; 143(4):514-26. PubMed ID: 25780003
[TBL] [Abstract][Full Text] [Related]
3. Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy.
Rivinius R; Helmschrott M; Ruhparwar A; Schmack B; Klein B; Erbel C; Gleissner CA; Akhavanpoor M; Frankenstein L; Darche FF; Thomas D; Ehlermann P; Bruckner T; Katus HA; Doesch AO
Drug Des Devel Ther; 2015; 9():93-102. PubMed ID: 25552900
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
[TBL] [Abstract][Full Text] [Related]
5. Impact of de novo everolimus-based immunosuppression on incisional complications in heart transplantation.
Zuckermann A; Arizon JM; Dong G; Eisen HJ; Kobashigawa J; Lehmkuhl H; Ross H; Pelligrini C; Wang SS; Barten MJ
Transplantation; 2011 Sep; 92(5):594-600. PubMed ID: 21862955
[TBL] [Abstract][Full Text] [Related]
6. Non-melanoma skin cancer and its risk factors in an Austrian population of heart transplant recipients receiving induction therapy.
Geusau A; Dunkler D; Messeritsch E; Sandor N; Heidler G; Rödler S; Ankersmit J; Zuckermann A; Tschachler E
Int J Dermatol; 2008 Sep; 47(9):918-25. PubMed ID: 18937654
[TBL] [Abstract][Full Text] [Related]
7. Optimizing the immunosuppressive regimen in heart transplantation.
Eisen H; Ross H
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
[TBL] [Abstract][Full Text] [Related]
8. Nonmelanoma Skin Cancer Frequency and Risk Factors in Australian Heart and Lung Transplant Recipients.
De Rosa N; Paddon VL; Liu Z; Glanville AR; Parsi K
JAMA Dermatol; 2019 Jun; 155(6):716-719. PubMed ID: 30865218
[TBL] [Abstract][Full Text] [Related]
9. Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis.
Rodríguez-Perálvarez M; Guerrero-Misas M; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011639. PubMed ID: 28362060
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I.
Monchaud C; Marquet P
Clin Pharmacokinet; 2009; 48(7):419-62. PubMed ID: 19691367
[TBL] [Abstract][Full Text] [Related]
11. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
12. Incidence and clinical predictors of a subsequent nonmelanoma skin cancer in solid organ transplant recipients with a first nonmelanoma skin cancer: a multicenter cohort study.
Tessari G; Naldi L; Boschiero L; Nacchia F; Fior F; Forni A; Rugiu C; Faggian G; Sassi F; Gotti E; Fiocchi R; Talamini G; Girolomoni G
Arch Dermatol; 2010 Mar; 146(3):294-9. PubMed ID: 20231501
[TBL] [Abstract][Full Text] [Related]
13. Renal recovery after conversion to an everolimus-based immunosuppression in early and late heart transplant recipients: a 12-month analysis.
Michel S; Bigdeli AK; Hagl C; Meiser B; Kaczmarek I
Exp Clin Transplant; 2013 Oct; 11(5):429-34. PubMed ID: 24128136
[TBL] [Abstract][Full Text] [Related]
14. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
15. Incidence, risk factors, and preventative management of skin cancers in organ transplant recipients: a review of single- and multicenter retrospective studies from 2006 to 2010.
Mudigonda T; Levender MM; O'Neill JL; West CE; Pearce DJ; Feldman SR
Dermatol Surg; 2013 Mar; 39(3 Pt 1):345-64. PubMed ID: 23190408
[TBL] [Abstract][Full Text] [Related]
16. Genetics and nonmelanoma skin cancer in kidney transplant recipients.
Burke MT; Isbel N; Barraclough KA; Jung JW; Wells JW; Staatz CE
Pharmacogenomics; 2015 Jan; 16(2):161-72. PubMed ID: 25616102
[TBL] [Abstract][Full Text] [Related]
17. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid.
Balda S; Inza A; Odriozola N; Zárraga S; García-Erauskin G; Lampreabe I
Transplant Proc; 2009; 41(6):2095-8. PubMed ID: 19715841
[TBL] [Abstract][Full Text] [Related]
18. First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients.
Mackenzie KA; Wells JE; Lynn KL; Simcock JW; Robinson BA; Roake JA; Currie MJ
Nephrol Dial Transplant; 2010 Jan; 25(1):300-6. PubMed ID: 19783601
[TBL] [Abstract][Full Text] [Related]
19. De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: A trial-based linkage study.
Ying T; Wong G; Lim W; Kanellis J; Pilmore H; Campbell S; Masterson R; Walker R; O'Connell P; Russ G; Chadban S
Am J Transplant; 2018 Dec; 18(12):2977-2986. PubMed ID: 29802791
[TBL] [Abstract][Full Text] [Related]
20. Risk of nonmelanoma skin cancer with azathioprine use.
Maddox JS; Soltani K
Inflamm Bowel Dis; 2008 Oct; 14(10):1425-31. PubMed ID: 18383175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
